Literature DB >> 25911336

EASL Recommendations on Treatment of Hepatitis C 2015.

.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25911336     DOI： 10.1016/j.jhep.2015.03.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  365 in total

Review 1.  Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Gene D Morse
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

2.  Therapy: Avoiding treatment failures associated with HCV resistance.

Authors:  Jean-Michel Pawlotsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-27       Impact factor: 46.802

3.  Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?

Authors:  Beth Woods; Rita Faria; Susan Griffin
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

Review 4.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Shiv K Sarin; Shivaram P Singh; Yogesh K Chawla; Rakesh Aggarwal; Deepak Amarapurkar; Anil Arora; Vinod K Dixit; Ajit Sood; Samir Shah; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Gaurav Pande; Aabha Nagral; Premashis Kar; Abraham Koshy; Amarender S Puri; C E Eapen; Sandeep Thareja
Journal:  J Clin Exp Hepatol       Date:  2015-09-21

Review 5.  [Specific infections in organ transplantation].

Authors:  M Cornberg; B Schlevogt; J Rademacher; A Schwarz; M Sandherr; G Maschmeyer
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

6.  Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.

Authors:  Youssef K Ahmad; Salwa Tawfeek; Mohamed Sharaf-Eldin; Hassan E Elbatea; Abdelrahman Kobtan; Ferial El-Kalla; Rehab Badawi; Sherief Abd-Elsalam
Journal:  Hosp Pharm       Date:  2017-04

7.  Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

Authors:  Luis Margusino-Framiñán; Purificación Cid-Silva; Sandra Rotea-Salvo; Álvaro Mena-de-Cea; Francisco Suárez-López; Pilar Vázquez-Rodríguez; Manuel Delgado-Blanco; Ana Isabel Sanclaudio-Luhia; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal:  Eur J Hosp Pharm       Date:  2020-02-07

8.  Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders.

Authors:  Hirsh D Trivedi; Steven C Lin; Daryl T Y Lau
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-10

Review 9.  HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.

Authors:  Marianne Martinello; Behzad Hajarizadeh; Jason Grebely; Gregory J Dore; Gail V Matthews
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

10.  Impact of Hepatitis C Virus/Schistosoma mansoni Coinfection on the Circulating Levels of HCV-NS4 Protein and Extracellular-Matrix Deposition in Patients with Different Hepatic Fibrosis Stages.

Authors:  Abdelfattah M Attallah; Sanaa O Abdallah; Mohamed S Albannan; Mohamed M Omran; Ahmed A Attallah; Khaled Farid
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.